Analysis of Keloid Response to 5-Fluorouracil Treatment and Long-Term Prevention of Keloid Recurrence.


Journal

Plastic and reconstructive surgery
ISSN: 1529-4242
Titre abrégé: Plast Reconstr Surg
Pays: United States
ID NLM: 1306050

Informations de publication

Date de publication:
02 2019
Historique:
pubmed: 12 12 2018
medline: 6 4 2019
entrez: 12 12 2018
Statut: ppublish

Résumé

Keloids are benign fibroproliferative skin tumors that can cause disfigurement and disability. Although they frequently recur after excision or medical management and can affect 6 to 16 percent of African Americans, there is no gold standard therapy. Keloids are challenging to study because there are no animal or in vitro models of this disorder. This makes it very difficult to validate data from treated tissue samples or cells and develop targeted therapies for this disease. In this study, the authors demonstrate that intralesional 5-fluorouracil injection after keloid excision prevents recurrence for 2 years, with no reported adverse events. The authors analyze the expression of treated and untreated biopsy specimens of the same keloids in their native context to capture insights that may be missed by in vitro cell culture models and correct for intrakeloid variability. Random forest analysis of the microarray data dramatically increased the statistical power of the authors' results, permitting hypothesis-free creation of a gene expression profile of 5-fluorouracil-treated keloids. Through this analysis, the authors found a set of genes, including YAP1 and CCL-2, whose expression changes predict 5-fluorouracil therapy status and include genes that have not previously been associated with keloid biology and are of unknown function. The authors further describe keloid heterogeneity for the first time using multidimensional analysis of their microarray results. The methods and tools the authors developed in this research may overcome some of the challenges in studying keloids and developing effective treatments for this disease. CLINICAL QUESTION/LEVEL OF EVIDENCE:: Therapeutic, V.

Identifiants

pubmed: 30531622
doi: 10.1097/PRS.0000000000005257
pmc: PMC6349497
mid: NIHMS1508254
pii: 00006534-201902000-00028
doi:

Substances chimiques

Adaptor Proteins, Signal Transducing 0
CCL2 protein, human 0
Chemokine CCL2 0
Phosphoproteins 0
Transcription Factors 0
YAP-Signaling Proteins 0
YAP1 protein, human 0
Fluorouracil U3P01618RT

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

490-494

Subventions

Organisme : NLM NIH HHS
ID : R01 LM008111
Pays : United States
Organisme : NLM NIH HHS
ID : R01 LM009254
Pays : United States
Organisme : NCATS NIH HHS
ID : TL1 TR001104
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001105
Pays : United States

Références

Exp Ther Med. 2016 Dec;12(6):3633-3641
pubmed: 28101157
Dermatol Reports. 2015 May 21;7(2):5880
pubmed: 26236447
Methods Mol Biol. 2016;1502:203-11
pubmed: 27115504
J Immunol. 2010 Oct 15;185(8):4651-8
pubmed: 20844197
J Biol Chem. 2015 Jun 5;290(23):14717-28
pubmed: 25918170
Indian J Dermatol Venereol Leprol. 2011 Jan-Feb;77(1):94-100
pubmed: 21220896
Wounds. 2009 Feb;21(2):57-63
pubmed: 25903026
FEBS Lett. 2014 Aug 19;588(16):2663-70
pubmed: 24747426
Br J Dermatol. 2015 Sep;173(3):690-700
pubmed: 25712143
Wound Repair Regen. 2013 Jul-Aug;21(4):530-44
pubmed: 23815228
Plast Reconstr Surg. 2012 Mar;129(3):648-656
pubmed: 22373972
J Drugs Dermatol. 2016 Nov 1;15(11):1442-1447
pubmed: 28095559
J Am Coll Clin Wound Spec. 2016 Nov 30;7(1-3):1-7
pubmed: 28053861
J Invest Dermatol. 2014 Feb;134(2):518-525
pubmed: 24108406
Front Med (Lausanne). 2015 Sep 03;2:59
pubmed: 26389119
Ann Plast Surg. 2014;72(6):711-9
pubmed: 24835866
BMC Bioinformatics. 2006 Jan 06;7:3
pubmed: 16398926
Am J Physiol Lung Cell Mol Physiol. 2015 Feb 15;308(4):L344-57
pubmed: 25502501
Genet Mol Res. 2014 Apr 14;13(2):2727-38
pubmed: 24782087
Genomics. 2012 Jun;99(6):323-9
pubmed: 22546560
Clin Cancer Res. 2005 Aug 15;11(16):5678-85
pubmed: 16115903
Hum Pathol. 2012 Nov;43(11):2024-32
pubmed: 22617232
Plast Reconstr Surg. 2014 Oct;134(4):561e-573e
pubmed: 25357050

Auteurs

Ryan LaRanger (R)

From the Departments of Cell Biology and Plastic Surgery, University of Texas Southwestern Medical Center; and the Division of Plastic Surgery, University of Colorado.

Anis Karimpour-Fard (A)

From the Departments of Cell Biology and Plastic Surgery, University of Texas Southwestern Medical Center; and the Division of Plastic Surgery, University of Colorado.

Christopher Costa (C)

From the Departments of Cell Biology and Plastic Surgery, University of Texas Southwestern Medical Center; and the Division of Plastic Surgery, University of Colorado.

David Mathes (D)

From the Departments of Cell Biology and Plastic Surgery, University of Texas Southwestern Medical Center; and the Division of Plastic Surgery, University of Colorado.

Woodring E Wright (WE)

From the Departments of Cell Biology and Plastic Surgery, University of Texas Southwestern Medical Center; and the Division of Plastic Surgery, University of Colorado.

Tae Chong (T)

From the Departments of Cell Biology and Plastic Surgery, University of Texas Southwestern Medical Center; and the Division of Plastic Surgery, University of Colorado.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH